{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:10:22Z","timestamp":1790727022342,"version":"4.1.0"},"reference-count":21,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Duke School of Medicine"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Prognosis of metastatic pheochromocytoma\/paraganglioma following 131-Iodine metaiodobenzylguanidine (MIBG) is incompletely characterized due to small samples and shorter follow-up in these rare, often indolent tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To describe long-term survival, frequency, and prognostic impact of imaging, biochemical, and symptomatic response to 131-I MIBG.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective chart and imaging review at a tertiary referral center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Six hundred sixty-eight person-years of follow-up in 125 patients with metastatic pheochromocytoma\/paraganglioma with progression through prior multimodal treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Median 18 800 MBq 131-I MIBG.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Overall survival, Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST) imaging response, symptomatic response per chart review, and biochemical response (20% change over 2 consecutive assays of catecholamines, vanillylmandelic acid, metanephrines, or chromogranin A).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median survival standard deviation [SD] from diagnosis was 11.5 years [2.4]; following metastasis, 6.5 years [0.8]; post treatment, 4.3 years [0.7]. Among 88 participants with follow-up imaging, 1% experienced complete response, 33% partial response, 53% stability, and 13% progression. Fifty-one percent showed subsequent progression, median progression-free survival [SD] of 2.0 years [0.6]. Stability\/response vs progression at first imaging follow-up (3\u20136 months) predicted improved survival, 6.3 vs 2.4 years (P = 0.021). Fifty-nine percent of 54 patients demonstrated biochemical response. Fifty percent of these relapsed, with median time to laboratory progression [SD] of 2.8 years [0.7]. Biochemical response did not predict extended survival. Seventy-five percent of 83 patients reported improvement in pretreatment symptoms, consisting primarily of pain (42%), fatigue (27%), and hypertension (14%). Sixty-one percent of these patients experienced subsequent symptomatic progression at median [SD] 1.8 years [0.4]. Symptomatic response did not predict extended survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Imaging, symptomatic, and laboratory response to multimodal treatment including high-dose 131-I MIBG were achieved on long-term follow-up in metastatic pheochromocytoma or paraganglioma. Imaging response at 3 to 6 months was prognostic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgz074","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T22:43:10Z","timestamp":1571179390000},"page":"e494-e501","source":"Crossref","is-referenced-by-count":36,"title":["Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG"],"prefix":"10.1210","volume":"105","author":[{"given":"Matthew P","family":"Thorpe","sequence":"first","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California San Francisco , San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Morse","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-9697","authenticated-orcid":false,"given":"Salvador","family":"Borges-Neto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Duke University Medical Center , Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"issue":"1","key":"2023042820354327600_CIT0001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/his.13402","article-title":"Pathology and genetics of phaeochromocytoma and paraganglioma","volume":"72","author":"Turchini","year":"2018","journal-title":"Histopathology."},{"key":"2023042820354327600_CIT0002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","article-title":"Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review","volume":"51","author":"Berends","year":"2018","journal-title":"Eur J Intern Med."},{"issue":"4","key":"2023042820354327600_CIT0003","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr Oncol Rep."},{"issue":"3","key":"2023042820354327600_CIT0004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol."},{"issue":"4","key":"2023042820354327600_CIT0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0090-4295(98)00612-8","article-title":"Pheochromocytomas: can malignant potential be predicted?","volume":"53","author":"John","year":"1999","journal-title":"Urology."},{"issue":"9","key":"2023042820354327600_CIT0006","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2023042820354327600_CIT0007","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1210\/jc.2004-1398","article-title":"Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma","volume":"90","author":"Amar","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2023042820354327600_CIT0008","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr Oncol Rep."},{"issue":"9","key":"2023042820354327600_CIT0009","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/eci.12495","article-title":"Metastatic pheochromocytoma and paraganglioma","volume":"45","author":"Angelousi","year":"2015","journal-title":"Eur J Clin Invest."},{"issue":"3","key":"2023042820354327600_CIT0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.semnuclmed.2016.01.011","article-title":"I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma","volume":"46","author":"Carrasquillo","year":"2016","journal-title":"Semin Nucl Med."},{"issue":"11","key":"2023042820354327600_CIT0011","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest."},{"issue":"5","key":"2023042820354327600_CIT0012","first-page":"518","article-title":"The Social Security Death Index (SSDI) most accurately reflects true survival for older oncology patients","volume":"3","author":"Huntington","year":"2013","journal-title":"Am J Cancer Res."},{"issue":"1","key":"2023042820354327600_CIT0013","first-page":"6","article-title":"Validation of the Social Security Death Index (SSDI): an important readily-available outcomes database for researchers","volume":"9","author":"Quinn","year":"2008","journal-title":"West J Emerg Med."},{"key":"2023042820354327600_CIT0014","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-1-59745-530-5_17","article-title":"Overview of missing data techniques","volume":"404","author":"D\u2019Agostino","year":"2007","journal-title":"Methods Mol Biol."},{"issue":"6","key":"2023042820354327600_CIT0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/10543400903242795","article-title":"An overview of practical approaches for handling missing data in clinical trials","volume":"19","author":"DeSouza","year":"2009","journal-title":"J Biopharm Stat."},{"issue":"9","key":"2023042820354327600_CIT0016","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/jcm7090242","article-title":"Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine","volume":"7","author":"Kimura","year":"2018","journal-title":"J Clin Med."},{"issue":"1","key":"2023042820354327600_CIT0017","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.surg.2016.05.050","article-title":"SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma","volume":"161","author":"Assadipour","year":"2017","journal-title":"Surgery."},{"issue":"7","key":"2023042820354327600_CIT0018","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/cncr.31916","article-title":"The who, when, and why of primary adrenal malignancies: insights into the epidemiology of a rare clinical entity","volume":"125","author":"Chandrasekar","year":"2019","journal-title":"Cancer."},{"issue":"9","key":"2023042820354327600_CIT0019","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2023042820354327600_CIT0020","first-page":"469","article-title":"Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma\/paraganglioma or metastatic carcinoid","volume":"24","author":"Coleman","year":"2009","journal-title":"Cancer Biother Radiopharm."},{"issue":"5","key":"2023042820354327600_CIT0021","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz074\/30153708\/dgz074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/e494\/50126982\/jcem_105_3_e494.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/e494\/50126982\/jcem_105_3_e494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T20:36:37Z","timestamp":1682714197000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/3\/e494\/5588089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,10,11]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz074","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,10,11]]}}}